文献速递肿瘤 PET/CT核素与放射性配体治疗

硼酸基成纤维细胞活化蛋白α靶向诊疗剂PNT6555用于FAP阳性肿瘤显像与治疗的临床前开发

Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
PubMed 文献 · J Nucl Med · 2024-01-02

研究合成三种DOTA-FAPI化合物PNT6555、PNT6952和PNT6522,评价其对FAP的抑制选择性、68Ga标记显像及177Lu、225Ac、161Tb标记治疗活性。177Lu-PNT6555在168小时内肿瘤累积显著高于另两种,177Lu-PNT6555产生最大肿瘤生长延迟和动物生存获益。225Ac-PNT6555和161Tb-PNT6555在最佳剂量下分别产生80%和100%生存。

要点

  • 68Ga-PNT6555和68Ga-PNT6952给药后60分钟呈肿瘤选择性暴露并持续累积。
  • 177Lu-PNT6555在168小时内肿瘤累积显著高于177Lu-PNT6952和177Lu-PNT6522。
  • 三种177Lu-DOTA-FAPI在耐受剂量下均有显著抗肿瘤活性,177Lu-PNT6555生存获益最大。

核心结论

  • PNT6555有潜力作为FAP阳性癌症的诊疗一体化药物进行临床转化。

研究设计与样本

  • 研究合成并表征PNT6555、PNT6952和PNT6522三种DOTA-FAPI,评价其对可溶性和细胞膜FAP的效价与选择性。
  • 在表达小鼠FAP的人胚胎肾细胞来源肿瘤异种移植小鼠中评价镥螯合类似物的细胞摄取、生物分布和药代动力学。
  • 通过直接器官测定和小动物PET评价68Ga螯合DOTA-FAPI的诊断潜力,并通过直接器官测定和SPECT评价177Lu螯合DOTA-FAPI的肿瘤选择性递送。
  • 使用表达小鼠FAP的人胚胎肾细胞来源肿瘤评价177Lu、225Ac或161Tb螯合类似物的抗肿瘤活性。

主要发现

  • DOTA-FAPI及其natGa和natLu螯合物对人源和小鼠源FAP均有强效抑制作用,对脯氨酰内肽酶和二肽基肽酶4活性大幅降低。
  • 68Ga-PNT6555和68Ga-PNT6952显示快速肾脏清除和肿瘤持续累积,给药后60分钟呈肿瘤选择性暴露。
  • 177Lu-PNT6555在168小时内肿瘤累积显著高于177Lu-PNT6952和177Lu-PNT6522。
  • 三种177Lu-DOTA-FAPI在耐受良好剂量下均显示显著抗肿瘤活性,177Lu-PNT6555产生最大肿瘤生长延迟和动物生存获益。
  • 225Ac-PNT6555和161Tb-PNT6555在最佳剂量下分别产生80%和100%生存,疗效相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The overexpression of fibroblast activation protein-α (FAP) in solid cancers relative to levels in normal tissues has led to its recognition as a target for delivering agents directly to tumors. Radiolabeled quinoline-based FAP ligands have established clinical feasibility for tumor imaging, but their therapeutic potential is limited due to suboptimal tumor retention, which has prompted the search for alternative pharmacophores. One such pharmacophore is the boronic acid derivative N-(pyridine-4-carbonyl)-d-Ala-boroPro, a potent and selective FAP inhibitor (FAPI). In this study, the diagnostic and therapeutic (theranostic) potential of N-(pyridine-4-carbonyl)-d-Ala-boroPro-based metal-chelating DOTA-FAPIs was evaluated. Methods: Three DOTA-FAPIs, PNT6555, PNT6952, and PNT6522, were synthesized and characterized with respect to potency and selectivity toward soluble and cell membrane FAP; cellular uptake of the Lu-chelated analogs; biodistribution and pharmacokinetics in mice xenografted with human embryonic kidney cell-derived tumors expressing mouse FAP; the diagnostic potential of 68Ga-chelated DOTA-FAPIs by direct organ assay and small-animal PET; the antitumor activity of 177Lu-, 225Ac-, or 161Tb-chelated analogs using human embryonic kidney cell-derived tumors expressing mouse FAP; and the tumor-selective delivery of 177Lu-chelated DOTA-FAPIs via direct organ assay and SPECT. Results: DOTA-FAPIs and their natGa and natLu chelates exhibited potent inhibition of human and mouse sources of FAP and greatly reduced activity toward closely related prolyl endopeptidase and dipeptidyl peptidase 4. 68Ga-PNT6555 and 68Ga-PNT6952 showed rapid renal clearance and continuous accumulation in tumors, resulting in tumor-selective exposure at 60 min after administration. 177Lu-PNT6555 was distinguished from 177Lu-PNT6952 and 177Lu-PNT6522 by significantly higher tumor accumulation over 168 h. In therapeutic studies, all 3 177Lu-DOTA-FAPIs exhibited significant antitumor activity at well-tolerated doses, with 177Lu-PNT6555 producing the greatest tumor growth delay and animal survival. 225Ac-PNT6555 and 161Tb-PNT6555 were similarly efficacious, producing 80% and 100% survival at optimal doses, respectively. Conclusion: PNT6555 has potential for clinical translation as a theranostic agent in FAP-positive cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Poplawski SE, Hallett RM, Dornan MH, et al. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors. J Nucl Med. 2024. PMID: 38050111. doi:10.2967/jnumed.123.266345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。